🎉 M&A multiples are live!
Check it out!

Kura Oncology Valuation Multiples

Discover revenue and EBITDA valuation multiples for Kura Oncology and similar public comparables like Vivoryon Therapeutics, Benevolent AI, and Julphar.

Kura Oncology Overview

About Kura Oncology

Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company’s pipeline consists of small molecule drug candidates targeting cancer signaling pathways.


Founded

2007

HQ

United States of America
Employees

192

Financials

LTM Revenue $76.6M

LTM EBITDA -$211M

EV

-$238M

Valuation Multiples

Multiples.vc

Sign up to see

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Kura Oncology Financials

Kura Oncology has a last 12-month revenue of $76.6M and a last 12-month EBITDA of -$211M.

In the most recent fiscal year, Kura Oncology achieved revenue of $53.9M and an EBITDA of -$169M.

Kura Oncology expects next 12-month revenue of  XXX    and NTM EBITDA of  XXX

See Kura Oncology valuation multiples based on analyst estimates

Kura Oncology P&L

FY 2023 FY 2024 FY 2025 LTM NTM
Revenue n/a $53.9M XXX XXX XXX
Gross Profit n/a n/a XXX XXX XXX
Gross Margin NaN% NaN% XXX XXX XXX
EBITDA -$150M -$169M XXX XXX XXX
EBITDA Margin -Infinity% -315% XXX XXX XXX
Net Profit -$136M -$153M XXX XXX XXX
Net Margin -Infinity% -283% XXX XXX XXX
Net Debt n/a n/a XXX XXX XXX

Financial data powered by Morningstar, Inc.

Kura Oncology Stock Performance

As of April 15, 2025, Kura Oncology's stock price is $6.

Kura Oncology has current market cap of $473M, and EV of -$238M.

See Kura Oncology trading valuation data

Kura Oncology Stock Data

EV Market Cap Price 1D Price 1M Price 3M Price 12M EPS
-$238M $473M XXX XXX XXX XXX $-1.96

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Sign Up

Kura Oncology Valuation Multiples

As of April 15, 2025, Kura Oncology has market cap of $473M and EV of -$238M.

Kura Oncology's trades at -3.1x LTM EV/Revenue multiple, and 1.1x LTM EBITDA.

Analysts estimate Kura Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See valuation multiples for Kura Oncology and 10K+ public comps

Kura Oncology Financial Valuation Multiples

FY 2024 FY 2025E FY 2026E FY 2027E
EV -$238M XXX XXX XXX
EV/Revenue -4.4x XXX XXX XXX
EV/EBITDA 1.4x XXX XXX XXX
P/E -2.7x XXX XXX XXX
P/E/Growth n/a XXX XXX XXX
EV/FCF -1.8x XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Kura Oncology Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Sign Up

Kura Oncology Valuation Multiples

Kura Oncology's NTM/LTM revenue growth is 95%

Kura Oncology's revenue per employee for the last fiscal year averaged $0.3M, while opex per employee averaged $1.3M for the same period.

Over next 12 months, Kura Oncology's ratio of sales and marketing spend to revenue is estimated to be  XXX , while its R&D spend to revenue to be  XXX .

Analysts estimate Kura Oncology's 2025E EV/Revenue multiple at  XXX and 2025E EV/EBITDA multiple at  XXX

See operational valuation multiples for Kura Oncology and other 10K+ public comps

Kura Oncology Operational Valuation Multiples

FY 2024 NTM FY 2025E FY 2026E FY 2027E
Revenue Growth Infinity% XXX XXX XXX XXX
EBITDA Margin -315% XXX XXX XXX XXX
EBITDA Growth 13% XXX XXX XXX XXX
Rule of 40 (SaaS-only) -220% XXX XXX XXX XXX
Revenue per Employee $0.3M XXX XXX XXX XXX
Opex per Employee $1.3M XXX XXX XXX XXX
S&M Expenses to Revenue n/a XXX XXX XXX XXX
G&A Expenses to Revenue 143% XXX XXX XXX XXX
R&D Expenses to Revenue 315% XXX XXX XXX XXX
Opex to Revenue 459% XXX XXX XXX XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics
Pharma Analytics
Private Equity
ERP Software
Developer Tools
Consumer SaaS
Streaming Platforms

Kura Oncology Public Comps

See public comps and valuation multiples for Drug Development & Therapeutics comps
EV/Revenue EV/EBITDA
2025E 2026E 2027E 2025E 2026E 2027E
Julphar XXX XXX XXX XXX XXX XXX
Benevolent AI XXX XXX XXX XXX XXX XXX
Galapagos XXX XXX XXX XXX XXX XXX
Pharming XXX XXX XXX XXX XXX XXX
Vivoryon Therapeutics XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX
XXXXXXXX XXX XXX XXX XXX XXX XXX

Valuation data powered by FactSet, Inc.

Kura Oncology M&A and Investment Activity

Kura Oncology acquired  XXX companies to date.

Last acquisition by Kura Oncology was  XXXXXXXX, XXXXX XXXXX XXXXXX . Kura Oncology acquired  XXXXXXXX for  XXX (EV/Revenue multiple of  XXX ).

See M&A valuation multiples

Latest Acquisitions by Kura Oncology

Acquired Company EV EV/Revenue EV/EBITDA
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX
XXXXXXXXX XXX XXX XXX

Get Verified M&A Valuation Multiples

Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.

Sign Up

About Kura Oncology

When was Kura Oncology founded? Kura Oncology was founded in 2007.
Where is Kura Oncology headquartered? Kura Oncology is headquartered in United States of America.
How many employees does Kura Oncology have? As of today, Kura Oncology has 192 employees.
Who is the CEO of Kura Oncology? Kura Oncology's CEO is Dr. Troy E. Wilson, PhD, J.D..
Is Kura Oncology publicy listed? Yes, Kura Oncology is a public company listed on NAS.
What is the stock symbol of Kura Oncology? Kura Oncology trades under KURA ticker.
When did Kura Oncology go public? Kura Oncology went public in 2015.
Who are competitors of Kura Oncology? Similar companies to Kura Oncology include e.g. Julphar, Benevolent AI, Galapagos, Pharming.
What is the current market cap of Kura Oncology? Kura Oncology's current market cap is $473M
What is the current revenue of Kura Oncology? Kura Oncology's last 12-month revenue is $76.6M.
What is the current EBITDA of Kura Oncology? Kura Oncology's last 12-month EBITDA is -$211M.
What is the current EV/Revenue multiple of Kura Oncology? Current revenue multiple of Kura Oncology is -3.1x.
What is the current EV/EBITDA multiple of Kura Oncology? Current EBITDA multiple of Kura Oncology is 1.1x.
Is Kura Oncology profitable? Yes, Kura Oncology is EBITDA-positive (as of the last 12 months).

Join Now Or Talk To Us

Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.